The present disclosure provides a novel thrombin action inhibitor, a composition for preventing skin disorders caused by pollens, and a cosmetic or non-therapeutic method for preventing skin disorders caused by pollens. More specifically, by using glutathione or a salt thereof as an active ingredient, a thrombin action inhibitor or a composition for preventing skin disorders caused by pollens can be prepared, and the inhibitor or the composition can be used in a cosmetic or non-therapeutic method for preventing skin disorders caused by pollens.

An anti-oxidizing agent or skin stress suppressing agent was provided with.

An anti-oxidizing agent or skin stress suppressing agent comprising a wavelength conversion substance as an active ingredient; a composition and a product comprising the anti-oxidizing agent or skin stress suppressing agent; and a method for suppressing oxidization and skin stress of skin using thereof were provided with. The present invention can exhibit a desirable effect on skin by effectively making use of ultraviolet light to suppress skin cells.

Provided herein are methods and compositions for preventing atopic march and treating a skin condition.

A composition of an anti-psoriatic drug and methods of applying the anti-psoriatic drug for transdermal delivery of nanoparticles and entry into skin cells are provided. The composition of the anti-psoriatic drug includes a core having at least one gold nanoparticle, a shell of polyethylene glycol (PEG) strands conjugated to the core, and a plurality of alkyl groups conjugated to the shell of PEG strands. Moreover, a chain length of the plurality of alkyl groups, chain loading of the plurality of alkyl groups, or a diameter of the core is configured to optimize a distribution of the composition in the skin cells. The distribution may include skin permeability or an entry into keratinocytes. Further, methods of modulating effectiveness of the anti-psoriatic drug for inhibiting development of a psoriasis phenotype or for treatment of the psoriasis phenotype are provided.

Provided are methods for preventing, ameliorating, or treating a skin disorder, disease, or condition with a casein kinase 1 inhibitor. Also provided are methods of increasing skin pigmentation or sunburn protection by inhibiting casein kinase 1.

The present disclosure relates to a composition comprising (20S,24R)-6-O-β-D-glucopyranosyl(1.fwdarw.2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. In addition, it relates to a method for improving skin elasticity or skin wrinkles, which comprises administering an effective amount of (20S,24R)-6-O-β-D-glucopyranosyl(1.fwdarw.2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof. The novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof has a superior effect of improving skin elasticity and skin wrinkles.

The present disclosure relates to a composition comprising (20S,24R)-6-O-β-D-glucopyranosyl(1.fwdarw.2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. In addition, it relates to a method for improving skin elasticity or skin wrinkles, which comprises administering an effective amount of (20S,24R)-6-O-β-D-glucopyranosyl(1.fwdarw.2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof. The novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof has a superior effect of improving skin elasticity and skin wrinkles.

Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

Provided are methods for propagating mesenchymal stem cells (MSC), and particularly adipose derived stem cells, including incubating isolated cells obtained from a tissue or organ including MSC in a growth medium including an apoptosis inducing agent, under specified conditions. Further provided is an isolated cell population and kits for performing the methods.

Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.